Buda Juice (BUDA) raises $2,999,992.50 from full IPO over-allotment

Rhea-AI Filing Summary

Buda Juice, Inc. reported that Public Ventures, LLC (doing business as MDB Capital), the underwriter of its initial public offering, fully exercised its over-allotment option on January 21, 2026. This option exercise led the company to sell an additional 399,999 shares of common stock.

As a result, Buda Juice received additional gross proceeds of $2,999,992.50 before underwriting discounts, commissions, and offering expenses. This increases the cash raised from its IPO, providing more capital for the company following its recent market debut.

false 0002079720 0002079720 2026-01-21 2026-01-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 21, 2026

Buda Juice, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-43043		46-4069365
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

4030 Black Gold Drive,

Dallas, Texas 75247

(Address of principal executive offices)

Registrant’s telephone number, including area code: (214) 308-5003

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		BUDA		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 21, 2026, Buda Juice, Inc. (the “Company”) issued a press release announcing the exercise of the over-allotment option granted to the underwriters of its initial public offering (the “Initial Public Offering”). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information set forth in Item 7.01, including Exhibits 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

In connection with the previously reported Initial Public Offering of the Company’s common stock, par value $0.001 per share, on January 21, 2026, Public Ventures, LLC (d/b/a MDB CAPITAL) (“MDB”) exercised the over-allotment option in full, pursuant to the underwriting agreement, dated January 7, 2026, with MDB. As a result of the exercise of the over-allotment option, the Company received additional gross proceeds of $2,999,992.50 for the 399,999 shares of common stock, before underwriting discounts, commissions, and offering expenses.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibits
99.1		Press Release of Buda Juice, Inc. entitled “Buda Juice Announces Full Exercise of Underwriters’ Over-Allotment Option in Connection with Initial Public Offering” dated January 21, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 21, 2026	Buda Juice, Inc.
	By:	/s/ Horatio Lonsdale-Hands
	Name:	Horatio Lonsdale-Hands
	Title:	Chief Executive Officer

FAQ

What did Buda Juice, Inc. (BUDA) announce in this 8-K filing?

Buda Juice, Inc. announced that the underwriter of its initial public offering fully exercised its over-allotment option, resulting in the sale of additional shares of common stock.

How many additional Buda Juice (BUDA) shares were sold through the over-allotment option?

The full exercise of the over-allotment option resulted in the sale of 399,999 additional shares of Buda Juice’s common stock.

How much additional capital did Buda Juice (BUDA) raise from the over-allotment exercise?

Buda Juice received additional gross proceeds of $2,999,992.50 from the sale of the 399,999 over-allotment shares, before underwriting discounts, commissions, and offering expenses.

Who exercised the over-allotment option in Buda Juice’s IPO?

Public Ventures, LLC, doing business as MDB Capital, exercised the over-allotment option in full under the underwriting agreement dated January 7, 2026.

When was the over-allotment option in Buda Juice’s IPO exercised?

The over-allotment option was exercised on January 21, 2026 in connection with Buda Juice’s initial public offering.

Does this 8-K filing for Buda Juice (BUDA) include full financial statements?

No. The filing focuses on the exercise of the IPO over-allotment option and references a press release as Exhibit 99.1, rather than providing full financial statements.